J Korean Soc Transplant.  2009 Sep;23(2):130-134. 10.4285/jkstn.2009.23.2.130.

Malignancy in Renal Transplant Recipients

Affiliations
  • 1Division of Nephrology, Maryknoll Medical Center, Busan, Korea. drkongj@gmail.com

Abstract

With improved management of infectious and cardiovascular complications of renal transplant recipients, prolonged survival with long-term follow up duration, and increasing age of patients, cancer became an increasingly important cause of morbidity and mortality in transplant patients. Literatures indicate three to fivefold incidence of malignancy in solid organ transplant recipients compared with that of general population. Certain types of malignancy, such as skin cancer, Kaposi's sarcoma, lymphoma, cervical, oral and anogenital cancer, hepatocelluar and renal cell carcinoma are particularly reported to be high in incidence. Reduction of immunosuppressive medication is the first step to be considered for the management, especially for virus-associated cancer. The inhibitor of mammalian target of rapamycin(mTORi) suppresses the growth and proliferation of tumors in various animal models, cured Kaposi's sarcoma and seems to reduce the incidence of de novo malignancies of renal transplant recipients, and is therefore a valuable option for the management of cancer of these patients without increment of the risk of graft rejection.

Keyword

Malignancy; Kidney transplantation; mTOR inhibitor; Cancer screening

MeSH Terms

Carcinoma, Renal Cell
Early Detection of Cancer
Follow-Up Studies
Graft Rejection
Humans
Incidence
Kidney Transplantation
Lymphoma
Models, Animal
Resin Cements
Sarcoma, Kaposi
Skin Neoplasms
Transplants
Resin Cements
Full Text Links
  • JKSTN
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error